neurocoach.
My Care Plan

NEUROCOACH RESEARCH WATCH · ADHD · DEVICES

ADHD nerve stimulation: what the larger clinical trials actually found

A device can be FDA-cleared and still have uncertain benefits. Two papers from the same randomized trial reported no convincing advantage for external trigeminal nerve stimulation over a sham device in young people with ADHD.

Published by NeuroCoach November 2, 2026. Original reports: January 16 and October 28, 2026. Educational editorial content; independent clinical review pending.

ADHD support optionsMore research updates
Reading list (0) →

Saved in this browser. Sign in to sync across devices.

What is eTNS?

External trigeminal nerve stimulation (eTNS) delivers mild electrical pulses through electrodes placed on the forehead, typically overnight. The FDA cleared a prescription eTNS device for certain pediatric ADHD uses in 2019 based partly on a smaller sham-controlled study of 62 children. Clearance is not the same as proof that every promised benefit has been established, and it does not imply usefulness for autism, anxiety, OCD or Tourette syndrome.

The larger trial: 150 children and adolescents

Researchers randomly assigned 150 young people ages 8–18 with ADHD to four weeks of nightly active stimulation (75 participants) or a sham comparison (75 participants), in a multicenter, double-blind phase 2b trial. The average age was 12.6 in both groups. The original clinical-outcome paper was published online January 16, 2026, in Nature Medicine.

Both groups improved over time, but the difference between groups on the ADHD symptom scale was not statistically significant: adjusted mean difference 0.83 points (95% CI −2.47 to 4.13; P=0.622), with a standardized effect size of just 0.09. No serious adverse events were reported during the trial, and the short-term side-effect rates did not significantly differ. These data cannot rule out every rare or long-term risk.

What the October 28 paper added

A companion paper in the American Journal of Psychiatry, published October 28, analyzed attention, inhibition, time estimation, processing speed, variability in task performance, autonomic regulation and head movement in the same 150-person trial. It found no significant between-group advantages on cognitive or physiological measures at four weeks, or on cognitive outcomes at six-month follow-up.

These are two reports from one randomized trial, not two independent replications. The follow-up measures also do not establish the same degree of six-month safety information as a long-term trial designed for that purpose. These findings were in youth with ADHD; do not generalize them to other diagnoses or device designs.

What about medication, anxiety and co-occurring needs?

The trial allowed stable stimulant treatment for some participants; 39% were taking stimulants. Subgroup analyses for children not taking medication were also negative. A child with ADHD might also have learning needs, autism, anxiety, OCD, tics, sleep difficulties or sensory differences. The presence of these needs does not create evidence that eTNS treats them.

These findings should prompt more careful conversations about available options, not abrupt changes to an existing care plan or device use. Discuss device-specific eligibility, safety, cost, comfort and clinically meaningful goals with a qualified care team.

Practical, evidence-supported next steps

  • Clarify the goals that matter most: school participation, sleep, organization, communication, emotional well-being or family routines.
  • Ask about behavioral classroom supports, organizational-skills training, parent training where age-appropriate, and individualized educational accommodations.
  • Where medication is part of care, evaluate it with the treating clinician rather than changing it in response to a device headline.
  • Track meaningful day-to-day experiences—not only an app's attention score or a device manufacturer's promised mechanism.

Six questions before considering an ADHD device

  1. Is it FDA-cleared for this specific age group and use?
  2. What did the largest sham-controlled study find on meaningful ADHD symptoms?
  3. Are claimed gains in sleep, emotional regulation or executive function supported by controlled trials?
  4. What are the risks, discomforts, practical burden and financial costs?
  5. Does evidence address this person's medications and other diagnoses?
  6. How would benefit be measured, and when would a clinician reassess the plan?

NeuroCoach does not sell or endorse a stimulation device. An absence of statistical benefit in this trial is not a reason to stop an existing therapy without medical discussion.

Original sources and publication dates

Editorial status: Source-linked educational article, not independently clinically reviewed. Original trial and report dates are shown separately from this site's publication date. No personalized device or medication advice is provided.

Make a short list of care-team questions →